Amend | Jotup

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on:

Tuesday, April 2, 2024

SOUTH SAN FRANCISCO, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on March 29, 2024 it granted stock options to purchase an aggregate of 78,000 shares of common stock to five new employees, whose employment commenced in March 2024, as a material inducement to their employment.

Key Points:

SOUTH SAN FRANCISCO, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on March 29, 2024 it granted stock options to purchase an aggregate of 78,000 shares of common stock to five new employees, whose employment commenced in March 2024, as a material inducement to their employment.
The stock options that were granted are subject to an exercise price of $70.11 per share, which is equal to the closing price of the Company’s common stock on March 28, 2024, and will vest over 4 years, with 1/4th of the shares underlying the employee’s option vesting on the one-year anniversary of the applicable vesting commencement date and the remaining shares thereafter vesting monthly at a rate of 1/48th of the shares underlying each employee’s option over the subsequent 36 months, subject to the new employee’s continued service with the Company.
Each stock option has a 10-year term and is subject to the terms and conditions of the Company's Amended and Restated 2004 Equity Incentive Plan and the stock option agreement pursuant to which the option was granted.

Vior Announces $20 Million Private Placement

Retrieved on:

Wednesday, March 20, 2024

It is expected that approximately $13 million will be raised from FT Units and $7 million from Hard Units and Subscription Receipts.

Key Points:

It is expected that approximately $13 million will be raised from FT Units and $7 million from Hard Units and Subscription Receipts.
Each Hard Unit and Subscription Receipt will have an issue price of $0.125 and each FT Unit will have an issue price of $0.2225.
The Over-Allotment Option will be exercisable, in whole or in part, up to 48 hours prior to the Closing Date.
The parties are expected to enter into a definitive royalty option agreement (the “Royalty Option Agreement”).

Aterian Announces Reverse Stock Split

Retrieved on:

Wednesday, March 20, 2024

Amend, CUSIP, Aterian, Exercise, Security (finance)

NEW YORK, March 20, 2024 (GLOBE NEWSWIRE) -- Aterian, Inc. (Nasdaq: ATER) (“Aterian” or the “Company”) has announced a 1-for-12 reverse stock split of its common stock, effective with the market opening on Friday, March 22, 2024.

Key Points:

NEW YORK, March 20, 2024 (GLOBE NEWSWIRE) -- Aterian, Inc. (Nasdaq: ATER) (“Aterian” or the “Company”) has announced a 1-for-12 reverse stock split of its common stock, effective with the market opening on Friday, March 22, 2024.
The reverse split was authorized by the Company's shareholders on August 11, 2023, granting the Company's Board of Directors (the "Board") the power to determine the timing and ratio of the split.
Consequently, every twelve shares of issued common stock will be combined into one share of common stock.
The reverse split will result in a new CUSIP number (02156U200) for the Company's common stock, which are expected to begin trading on a split-adjusted basis from March 22, 2024.

NUTEX HEALTH ANNOUNCES 1-FOR-15 REVERSE STOCK SPLIT

Retrieved on:

Friday, April 5, 2024

Amend, CUSIP, Eastern Time Zone, Exercise, Nutex Health, Security (finance)

HOUSTON, April 5, 2024 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ: NUTX), today announced a 1-for-15 reverse stock split of its common stock effective with the market opening on Tuesday April 10, 2024.

Key Points:

HOUSTON, April 5, 2024 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ: NUTX), today announced a 1-for-15 reverse stock split of its common stock effective with the market opening on Tuesday April 10, 2024.
The reverse stock split is part of the Company's plan to regain compliance with the minimum bid price requirement for the continued listing on The Nasdaq Capital Market.
No fractional shares will be issued as a result of the reverse stock split.
In addition, the number of shares reserved for issuance under the Company's equity compensation plan immediately prior to the reverse stock split will be reduced proportionately.

RETRANSMISSION: Akanda Corp. Signs Share Purchase and Escrow Agreements for the Sale of Portuguese Assets to Somai Pharmaceuticals

Retrieved on:

Friday, March 1, 2024

CBPM, USD, Amend, Sale, RPK, Medicine, LDA, Patient, CBD, THC, Akanda, Schedule 2, Resolution

This strategic move underscores both companies' commitment to advancing the medical cannabis industry and enhancing patient access to high-quality cannabis treatments.

Key Points:

This strategic move underscores both companies' commitment to advancing the medical cannabis industry and enhancing patient access to high-quality cannabis treatments.
Under the terms of the Share Purchase Agreement, Somai will acquire RPK, Akanda's indirect Portuguese subsidiary, for a total consideration of Two Million United States Dollars (USD $2,000,000).
The execution of the Share Purchase Agreement and Escrow Agreement follows the Amended Non-Binding Letter of Intent ("LOI") announced on February 1, 2024, and represents a crucial step towards the transaction's completion.
The closing of the proposed sale is subject to customary due diligence, representations, warranties, covenants, indemnities, and other closing conditions.

Golden Star Filed Supplement to Proxy Statement

Retrieved on:

Thursday, March 7, 2024

Name, Attention, Letter, Proxy, Amend, Meeting, Proxy card, Supplement, Avenue, Finance Secretary (India), Accounting, Trust, Hudson Street, Eastern Time Zone, Commission, Security (finance)

Other than as indicated herein, no other changes have been made to the Proxy Statement or the proxy card as originally filed and mailed.

Key Points:

Other than as indicated herein, no other changes have been made to the Proxy Statement or the proxy card as originally filed and mailed.
Any references to the “Proxy Statement” are to the Proxy Statement as amended and supplemented by the Supplement and all the filed additional proxy statement supplements as indicated above.
The Amended Proxy Card differs from the proxy card previously made available to shareholders of the Company with the Proxy Statement, in that the enclosed Amended Proxy Card includes the Amended Proposal No.
The original Proxy Statement and proxy card were mailed to the Company’s shareholders of record on or about February 7, 2024.

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on:

Friday, March 1, 2024

SAN, Amend, Cytokinetics, Employment

SOUTH SAN FRANCISCO, Calif., March 01, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on February 29, 2024 it granted stock options to purchase an aggregate of 28,500 shares of common stock to three new employees, whose employment commenced in February 2024, as a material inducement to their employment.

Key Points:

SOUTH SAN FRANCISCO, Calif., March 01, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on February 29, 2024 it granted stock options to purchase an aggregate of 28,500 shares of common stock to three new employees, whose employment commenced in February 2024, as a material inducement to their employment.
The stock options that were granted are subject to an exercise price of $72.24 per share, which is equal to the closing price of the Company’s common stock on February 29, 2024, and will vest over 4 years, with 1/4th of the shares underlying the employee’s option vesting on the one-year anniversary of the applicable vesting commencement date and the remaining shares thereafter vesting monthly at a rate of 1/48th of the shares underlying each employee’s option over the subsequent 36 months, subject to the new employee’s continued service with the Company.
Each stock option has a 10-year term and is subject to the terms and conditions of the Company's Amended and Restated 2004 Equity Incentive Plan and the stock option agreement pursuant to which the option was granted.

Spectral Medical Announces Amendment and Extension of Exclusive Supply and Distribution Agreement With Baxter Healthcare Corporation

Retrieved on:

Wednesday, February 21, 2024

Baxter International, PMX, Sepsis, Intensive care unit, Amend, Investment, FDA, TSX, U.S. FDA, Risk, Baxter, Patient, Septic shock, United, Partnership, Pharmaceutical industry

TORONTO, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, is pleased to announce an extension to its supply and distribution agreement (the “Amended Agreement”) with Baxter Healthcare Corporation, a subsidiary of Baxter International Inc. (“Baxter”) (NYSE: BAX), originally entered into in February 2020.

Key Points:

TORONTO, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, is pleased to announce an extension to its supply and distribution agreement (the “Amended Agreement”) with Baxter Healthcare Corporation, a subsidiary of Baxter International Inc. (“Baxter”) (NYSE: BAX), originally entered into in February 2020.
Spectral is a Phase 3 company seeking U.S. FDA approval for its unique product for the treatment of patients with septic shock, Toraymyxin™ (“PMX”).
“Baxter’s continued commitment to Spectral as our exclusive supply and distribution partner being extended for a ten-year period upon U.S. FDA approval provides us with great confidence in our commercialization path,” said Chris Seto, CEO of Spectral Medical.
On February 15, 2024, Spectral announced that it had reached the 90-patient enrollment threshold and provided written notification to Baxter of this achievement.

Bannix Acquisition Corp. Announces Monthly Extension to Complete its Initial Business Combination

Retrieved on:

Tuesday, February 20, 2024

Sponsor, Amend

WEST HOLLYWOOD, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Bannix Acquisition Corp. (“Bannix”) announced today that its board of directors (the “Board”) has decided to extend the date by which Bannix must consummate an initial business combination (the “Deadline Date”) from February 14, 2024 for an additional month, to March 14, 2024.

Key Points:

WEST HOLLYWOOD, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Bannix Acquisition Corp. (“Bannix”) announced today that its board of directors (the “Board”) has decided to extend the date by which Bannix must consummate an initial business combination (the “Deadline Date”) from February 14, 2024 for an additional month, to March 14, 2024.
On March 9, 2023, Bannix filed the Amended Charter with the Secretary of State of the State of Delaware.
Also as previously announced, if an Extension is implemented, the sponsor of Bannix, Instant Fame LLC (the “Sponsor”), or its designees will deposit into the trust account, as a loan, the lesser of (x) $75,000 and (y) $0.07 for each share that is not redeemed in connection with the special meeting.
On February 15, 2024, the Board, at the request of the Sponsor, decided to implement the twelfth Extension and to extend the Deadline Date for an additional month to March 14, 2024.

NCLA Secures Truce in Federal Trade Commission’s Unjust War Against Innocent Startup Company

Retrieved on:

Friday, February 16, 2024

FTC, Court, Person, Amend, Dietary supplement, PPO, Complaint, COVID-19, NCLA, Advertising, Order, Congress, Supreme court

As a start-up, Ms. Lewis wrote to FTC at the pre-market stage, requesting guidance on her advertising before selling any product.

Key Points:

As a start-up, Ms. Lewis wrote to FTC at the pre-market stage, requesting guidance on her advertising before selling any product.
PPO and Ms. Lewis afterwards were not provided a warning letter, contrary to FTC’s usual practice.
NCLA pressed a Counterclaim that FTC’s structure is unconstitutional, which will be dismissed as part of this agreed-to Order.
NCLA will keep pressing this claim on behalf of other clients until the Supreme Court overturns Humphrey’s Executor.”
— Mark Chenoweth, President and Chief Legal Officer, NCLA